Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
agilon health, inc. stock logo
AGL
agilon health
$6.30
+1.0%
$5.34
$4.41
$21.52
$2.59B0.523.74 million shs3.90 million shs
Merus stock logo
MRUS
Merus
$53.24
-7.1%
$45.66
$19.81
$61.61
$3.12B1.11.29 million shs1.72 million shs
Progyny, Inc. stock logo
PGNY
Progyny
$26.95
+1.2%
$31.91
$23.90
$44.95
$2.57B1.511.63 million shs987,473 shs
Sotera Health stock logo
SHC
Sotera Health
$11.18
+0.8%
$11.29
$10.71
$19.40
$3.16B2.08968,376 shs1.96 million shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
agilon health, inc. stock logo
AGL
agilon health
0.00%+3.45%+30.43%+4.30%-68.31%
Merus stock logo
MRUS
Merus
0.00%-11.25%+12.08%+2.74%+145.12%
Progyny, Inc. stock logo
PGNY
Progyny
0.00%-0.19%-15.97%-25.18%-27.65%
Sotera Health stock logo
SHC
Sotera Health
0.00%-0.18%+2.47%-23.21%-20.65%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
agilon health, inc. stock logo
AGL
agilon health
1.4165 of 5 stars
4.11.00.00.01.90.00.6
Merus stock logo
MRUS
Merus
1.7503 of 5 stars
3.51.00.00.03.01.70.6
Progyny, Inc. stock logo
PGNY
Progyny
4.3412 of 5 stars
4.51.00.00.03.03.33.1
Sotera Health stock logo
SHC
Sotera Health
4.468 of 5 stars
4.33.00.00.01.34.23.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
agilon health, inc. stock logo
AGL
agilon health
2.16
Hold$9.0343.39% Upside
Merus stock logo
MRUS
Merus
3.00
Buy$63.8019.83% Upside
Progyny, Inc. stock logo
PGNY
Progyny
2.90
Moderate Buy$43.1159.97% Upside
Sotera Health stock logo
SHC
Sotera Health
2.67
Moderate Buy$16.9251.31% Upside

Current Analyst Ratings

Latest PGNY, AGL, SHC, and MRUS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/30/2024
agilon health, inc. stock logo
AGL
agilon health
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
5/30/2024
agilon health, inc. stock logo
AGL
agilon health
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$6.00
5/28/2024
Merus stock logo
MRUS
Merus
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$57.00 ➝ $93.00
5/28/2024
Merus stock logo
MRUS
Merus
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$65.00 ➝ $90.00
5/24/2024
agilon health, inc. stock logo
AGL
agilon health
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$6.40 ➝ $6.50
5/24/2024
Merus stock logo
MRUS
Merus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$66.00 ➝ $66.00
5/24/2024
Merus stock logo
MRUS
Merus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$65.00 ➝ $65.00
5/24/2024
Merus stock logo
MRUS
Merus
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$52.00 ➝ $61.00
5/21/2024
Sotera Health stock logo
SHC
Sotera Health
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$13.00
5/17/2024
Progyny, Inc. stock logo
PGNY
Progyny
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$46.00 ➝ $37.00
5/16/2024
Progyny, Inc. stock logo
PGNY
Progyny
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$48.00
(Data available from 6/2/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
agilon health, inc. stock logo
AGL
agilon health
$4.32B0.60N/AN/A$1.67 per share3.77
Merus stock logo
MRUS
Merus
$43.95M71.10N/AN/A$5.95 per share8.95
Progyny, Inc. stock logo
PGNY
Progyny
$1.09B2.36$0.67 per share40.16$6.00 per share4.49
Sotera Health stock logo
SHC
Sotera Health
$1.05B3.02$1.32 per share8.50$1.52 per share7.36

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
agilon health, inc. stock logo
AGL
agilon health
-$262.60M-$0.70N/AN/AN/A-5.67%-26.15%-9.33%8/1/2024 (Estimated)
Merus stock logo
MRUS
Merus
-$154.94M-$2.77N/AN/AN/A-390.36%-44.13%-33.08%8/5/2024 (Estimated)
Progyny, Inc. stock logo
PGNY
Progyny
$62.04M$0.6144.1828.671.855.53%11.61%8.28%8/1/2024 (Estimated)
Sotera Health stock logo
SHC
Sotera Health
$51.38M$0.1958.8515.11N/A5.09%48.47%6.58%8/1/2024 (Estimated)

Latest PGNY, AGL, SHC, and MRUS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024Q1 2024
Progyny, Inc. stock logo
PGNY
Progyny
$0.14$0.17+$0.03$0.17$289.41 million$278.08 million      
5/8/2024Q1 2024
Merus stock logo
MRUS
Merus
-$0.83-$0.59+$0.24-$0.59$8.94 million$7.89 million
5/7/2024Q1 2024
agilon health, inc. stock logo
AGL
agilon health
-$0.02$0.01+$0.03$0.03N/AN/A
5/2/2024Q1 2024
Sotera Health stock logo
SHC
Sotera Health
$0.12$0.11-$0.01$0.20$254.73 million$248.18 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
agilon health, inc. stock logo
AGL
agilon health
N/AN/AN/AN/AN/A
Merus stock logo
MRUS
Merus
N/AN/AN/AN/AN/A
Progyny, Inc. stock logo
PGNY
Progyny
N/AN/AN/AN/AN/A
Sotera Health stock logo
SHC
Sotera Health
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
agilon health, inc. stock logo
AGL
agilon health
0.04
1.33
1.33
Merus stock logo
MRUS
Merus
N/A
5.23
5.23
Progyny, Inc. stock logo
PGNY
Progyny
N/A
3.31
3.31
Sotera Health stock logo
SHC
Sotera Health
5.39
3.20
2.86

Ownership

Institutional Ownership

CompanyInstitutional Ownership
agilon health, inc. stock logo
AGL
agilon health
N/A
Merus stock logo
MRUS
Merus
96.14%
Progyny, Inc. stock logo
PGNY
Progyny
94.93%
Sotera Health stock logo
SHC
Sotera Health
91.03%

Insider Ownership

CompanyInsider Ownership
agilon health, inc. stock logo
AGL
agilon health
3.20%
Merus stock logo
MRUS
Merus
4.57%
Progyny, Inc. stock logo
PGNY
Progyny
12.30%
Sotera Health stock logo
SHC
Sotera Health
55.12%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
agilon health, inc. stock logo
AGL
agilon health
1,117411.26 million398.10 millionNot Optionable
Merus stock logo
MRUS
Merus
17258.69 million56.01 millionOptionable
Progyny, Inc. stock logo
PGNY
Progyny
56395.22 million83.51 millionOptionable
Sotera Health stock logo
SHC
Sotera Health
3,000283.07 million127.04 millionOptionable

PGNY, AGL, SHC, and MRUS Headlines

Recent News About These Companies

SHC Sotera Health Company

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

agilon health logo

agilon health

NYSE:AGL
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.
Merus logo

Merus

NASDAQ:MRUS
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Progyny logo

Progyny

NASDAQ:PGNY
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Sotera Health logo

Sotera Health

NASDAQ:SHC
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems. The company also provides microbiological and analytical chemistry testing, as well as technical assistance, regulatory consulting, and advisory services. It serves medical devices, pharmaceuticals, food safety, agricultural products, cancer treatment, and high-performance materials industries, as well as commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.